📊 NEPH Key Takeaways
Is NEPH a Good Investment? Thesis Analysis
Nephros demonstrates solid fundamental strength with 32.7% revenue growth, exceptional balance sheet liquidity (4.06x current ratio), and transition to profitability with positive free cash flow generation. However, the company remains micro-cap with thin 6.1% operating margins despite strong 61.9% gross margins, indicating elevated operating expenses relative to business scale.
Why Buy NEPH? Key Strengths
- Fortress balance sheet: debt-free with 4.06x current ratio, 2.89x quick ratio, and $5.4M cash representing 40% of assets
- Strong revenue growth of 32.7% YoY with exceptional 61.9% gross margins indicating pricing power in surgical devices
- Positive free cash flow of $1.6M (8.5% FCF margin) with minimal capex, demonstrating cash generation ability
- Recently achieved profitability with net income of $1.2M and positive net margin of 6.4%
- Minimal debt burden (Debt/Equity 0.01x) with 1146x interest coverage provides maximum financial flexibility
NEPH Investment Risks to Consider
- Micro-cap size ($18.8M revenue, $13.6M total assets) creates execution risk and limited organizational scale
- Operating margin of only 6.1% despite 61.9% gross margins indicates elevated SG&A costs relative to revenue base
- Very low absolute profitability ($1.2M net income) limits margin for error and financial cushion
- Early profitability stage (1513.5% YoY net income growth suggests prior year near-zero or negative earnings)
- Minimal capex ($55K) may signal underinvestment in growth infrastructure or product development needed for scaling
Key Metrics to Watch
- Operating margin expansion trajectory and SG&A leverage as revenue scales
- Revenue growth sustainability - whether 32.7% growth rate can be maintained
- Gross margin stability at 61.9% level as production volume increases
- Free cash flow maintenance and conversion rate relative to operating cash flow
- Working capital efficiency and cash balance trends relative to revenue growth
NEPH Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 4.06x current ratio provides a solid financial cushion.
NEPH Profitability Ratios
NEPH vs Healthcare Sector
How NEPHROS INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NEPH Overvalued or Undervalued?
Based on fundamental analysis, NEPHROS INC has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NEPH Balance Sheet & Liquidity
NEPH 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: NEPHROS INC's revenue has grown significantly by 81% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.01 reflects profitable operations.
NEPH Growth Metrics (YoY)
NEPH Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $3.5M | -$169.0K | $0.02 |
| Q2 2025 | $3.3M | -$169.0K | $0.02 |
| Q1 2025 | $3.5M | -$169.0K | $-0.02 |
| Q3 2024 | $3.5M | -$169.0K | $-0.02 |
| Q2 2024 | $3.3M | -$169.0K | $-0.03 |
| Q1 2024 | $3.5M | -$169.0K | $-0.02 |
| Q3 2023 | $2.4M | N/A | $-0.02 |
| Q2 2023 | $2.9M | N/A | $-0.04 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NEPH Capital Allocation
NEPH SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for NEPHROS INC (CIK: 0001196298)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NEPH
What is the AI rating for NEPH?
NEPHROS INC (NEPH) has an AI rating of BUY with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are NEPH's key strengths?
Claude: Fortress balance sheet: debt-free with 4.06x current ratio, 2.89x quick ratio, and $5.4M cash representing 40% of assets. Strong revenue growth of 32.7% YoY with exceptional 61.9% gross margins indicating pricing power in surgical devices.
What are the risks of investing in NEPH?
Claude: Micro-cap size ($18.8M revenue, $13.6M total assets) creates execution risk and limited organizational scale. Operating margin of only 6.1% despite 61.9% gross margins indicates elevated SG&A costs relative to revenue base.
What is NEPH's revenue and growth?
NEPHROS INC reported revenue of $18.8M.
Does NEPH pay dividends?
NEPHROS INC does not currently pay dividends.
Where can I find NEPH SEC filings?
Official SEC filings for NEPHROS INC (CIK: 0001196298) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NEPH's EPS?
NEPHROS INC has a diluted EPS of $0.11.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NEPH a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, NEPHROS INC has a BUY rating with 75% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is NEPH stock overvalued or undervalued?
Valuation metrics for NEPH: ROE of 11.7% (sector avg: 15%), net margin of 6.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NEPH stock in 2026?
Our dual AI analysis gives NEPHROS INC a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NEPH's free cash flow?
NEPHROS INC's operating cash flow is $1.6M, with capital expenditures of $55.0K. FCF margin is 8.5%.
How does NEPH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 6.4% (avg: 12%), ROE 11.7% (avg: 15%), current ratio 4.06 (avg: 2).